论文部分内容阅读
【摘要】 目的 探讨琥珀酸美托乐尔缓释片对高血压患者脉搏波速度的影响。方法 28例首次确诊的高血压患者与28例正常对照组对比分析血压、血糖、血脂和脉搏波速度,琥珀酸美托乐尔缓释片治疗12周后重复测量上述指标,前后对比分析血压和脉搏波速度的变化。结果 高血压患者收缩压(156.3±8.6)mm Hg比(112.6±11.9 mm Hg、舒张压(103.6±6.7)mm Hg比(68.2±8.9)mm Hg和脉搏波速度(1971.3±187.4)cm/s比(1187.2±198.5)cm/s显著高于正常对照组(P<0.05)。琥珀酸美托乐尔缓释片治疗12周后,患者心率(85.2±4.7)比(64.5±6.3)收缩压(156.3±8.6)mm Hg比(121.9±7.9)mm Hg、舒张压(103.6±6.7)mm Hg比(76.3±5.1)mm Hg和脉搏波速度(1971.3±187.4)cm/s 比(1236.5±186.3)cm/s)显著下降(P<0.05)。 结论 琥珀酸美托乐尔缓释片可以降低高血压患者的脉搏波速度,改善动脉顺应性。
【关键词】高血压;脉搏波速度; 琥珀酸美托乐尔缓释片
Effects of metoprolol succinate sustained release tablets on pulse wave velocity in patients with essential hypertension
LIU Heng liang,LIU Yang,GENG Guo ying,et al.Department of cardiology,Zhengzhou People’s hospital,Zhengzhou 450002,China
【Abstract】 Objective To evaluate the effects of metoprolol succinate sustained release tablets on Brachial ankle pulse wave velocity(baPWV)in patients with essential hypertension.Methods The levels of serum blood lipid and blood glucose,blood pressure,heart rate and baPWV were measured respectively in twenty eight patients with essential hypertension andtwenty eight healthy persons with normal blood pressure.After twelve weeks treated with metoprolol succinate sustained release tablets,The blood pressure and baPWV were measured again and were studied in patients with essential hypertension.Results The systolic blood pressure(156.3±8.6)mm Hg vs(112.6±11.9)mm Hg,diastolic blood pressure(103.6±6.7)mm Hg vs(68.2±8.9)mm Hg and baPWV(1971.3±187.4)cm/s vs(1187.2±198.5)cm/s in patients with essential hypertension were higher than that of healthy persons with normal blood pressure significantly(P<0.05),The heart rate(85.2±4.7)vs(64.5±6.3) beat/min,systolic blood pressure(156.3±8.6)mm Hg vs(121.9±7.9)mm Hg,diastolic blood pressure(103.6±6.7)mm Hg vs(76.3±5.1)mm Hg and baPWV(1971.3±187.4)cm/s vs(1236.5±186.3)cm/s were decreased significantly in patients with essential hypertension(P<0.05)after treated with metoprolol succinate sustained release tablets.Conclusion Metoprolol succinate sustained release tablets treated in patients with essential hypertension can decreased pulse wave velocity,impore elasticity of large arterise and increase the distensibility of aorta.
【Key words】Hypertension; Pulse wave velocity;Metoprolol succinate sustained release tablets
高血压己成为威胁人类健康的重大公共卫生问题,高血压是动脉硬化最常见的危险因素之一,也是引起脑卒中、心力衰竭、冠心病、肾功能不全的主要原因[1]。有效的预防高血压并发症的发生,不仅要使血压达标,还应包括对心、脑、肾等靶器官功能的保护。对心脏和血管功能的保护有助于减少高血压患者心脑血管事件的发生[2,3]。脉搏波速度(pulse wave velocity,PWV)是评价动脉僵硬度并预测高血压患者心、脑血管病发生和死亡的重要指标之一[4],β 受体阻滞剂琥珀酸美托乐尔缓释片是治疗高血压常用的药物之一,本研究旨在观察琥珀酸美托乐尔缓释片对高血压患者PWV的影响,以了解琥珀酸美托乐尔缓释片在降低血压的同时对大动脉功能的影响。
1 对象与方法
1.1 对象 选择2008年6月至2009年6月郑州人民医院健康体检发现且经心血管内科重复检查确诊,根据2005年中国高血压防治指南制订的诊断标准,排除继发性高血压、糖尿病、肾脏损害、失代偿性心力衰竭、病态窦房结综合征、第二、三度房室传导阻滞、支气管哮喘、慢性阻塞性肺病、外周血管病等,所有入选者1~2年内曾在我院体检,有档案可追踪的既往健康首次发现的高血压患者,换句话说,这些患者的高血压肯定是1~2年内新近发生,且从未接受过任何抗高血压药物治疗的的1~2级高血压患者28例,并随机抽取同时期健康体检者28例进行对比观察。
1.2 方法 使用日本Colin公司生产的动脉硬化检测仪(VP 1000,PWV/ABI型)进行检查,心电图为窦性心率,检查前记录患者的年龄、性别、身高、体重,检查时间统一安排在上午9 10点,室温保持在25℃左右进行测定,以臂 踝脉搏波速度(Brachial ankle pulse wave velocity,baPWV)作为评估大动脉弹性指标。患者平卧于检查床安静静息 15 min以上,四肢缚4个示波血压袖带,连接好肢导联和心电图电极,并将1个心音图PCG 传感器放置在心电图胸导联V4的位置上,4个袖带同时充放气,并监测心电图和 PCG。取左右两侧的baPWV平均值进行统计分析。检查结束后的次日给予琥珀酸美托乐尔缓释片47.5 mg,每06:00~08:00口服,4周内每周门诊测量一次血压,降压达标后每4周测量一次血压,不达标者,根据心率变化,如果患者心率>60次/min,增加剂量至95 mg,每早一次口服;如果心率<60次/min,加用钠催离1.5 mg,每早一次口服。12周后重复检查baPWV前后进行对比分析。
【关键词】高血压;脉搏波速度; 琥珀酸美托乐尔缓释片
Effects of metoprolol succinate sustained release tablets on pulse wave velocity in patients with essential hypertension
LIU Heng liang,LIU Yang,GENG Guo ying,et al.Department of cardiology,Zhengzhou People’s hospital,Zhengzhou 450002,China
【Abstract】 Objective To evaluate the effects of metoprolol succinate sustained release tablets on Brachial ankle pulse wave velocity(baPWV)in patients with essential hypertension.Methods The levels of serum blood lipid and blood glucose,blood pressure,heart rate and baPWV were measured respectively in twenty eight patients with essential hypertension andtwenty eight healthy persons with normal blood pressure.After twelve weeks treated with metoprolol succinate sustained release tablets,The blood pressure and baPWV were measured again and were studied in patients with essential hypertension.Results The systolic blood pressure(156.3±8.6)mm Hg vs(112.6±11.9)mm Hg,diastolic blood pressure(103.6±6.7)mm Hg vs(68.2±8.9)mm Hg and baPWV(1971.3±187.4)cm/s vs(1187.2±198.5)cm/s in patients with essential hypertension were higher than that of healthy persons with normal blood pressure significantly(P<0.05),The heart rate(85.2±4.7)vs(64.5±6.3) beat/min,systolic blood pressure(156.3±8.6)mm Hg vs(121.9±7.9)mm Hg,diastolic blood pressure(103.6±6.7)mm Hg vs(76.3±5.1)mm Hg and baPWV(1971.3±187.4)cm/s vs(1236.5±186.3)cm/s were decreased significantly in patients with essential hypertension(P<0.05)after treated with metoprolol succinate sustained release tablets.Conclusion Metoprolol succinate sustained release tablets treated in patients with essential hypertension can decreased pulse wave velocity,impore elasticity of large arterise and increase the distensibility of aorta.
【Key words】Hypertension; Pulse wave velocity;Metoprolol succinate sustained release tablets
高血压己成为威胁人类健康的重大公共卫生问题,高血压是动脉硬化最常见的危险因素之一,也是引起脑卒中、心力衰竭、冠心病、肾功能不全的主要原因[1]。有效的预防高血压并发症的发生,不仅要使血压达标,还应包括对心、脑、肾等靶器官功能的保护。对心脏和血管功能的保护有助于减少高血压患者心脑血管事件的发生[2,3]。脉搏波速度(pulse wave velocity,PWV)是评价动脉僵硬度并预测高血压患者心、脑血管病发生和死亡的重要指标之一[4],β 受体阻滞剂琥珀酸美托乐尔缓释片是治疗高血压常用的药物之一,本研究旨在观察琥珀酸美托乐尔缓释片对高血压患者PWV的影响,以了解琥珀酸美托乐尔缓释片在降低血压的同时对大动脉功能的影响。
1 对象与方法
1.1 对象 选择2008年6月至2009年6月郑州人民医院健康体检发现且经心血管内科重复检查确诊,根据2005年中国高血压防治指南制订的诊断标准,排除继发性高血压、糖尿病、肾脏损害、失代偿性心力衰竭、病态窦房结综合征、第二、三度房室传导阻滞、支气管哮喘、慢性阻塞性肺病、外周血管病等,所有入选者1~2年内曾在我院体检,有档案可追踪的既往健康首次发现的高血压患者,换句话说,这些患者的高血压肯定是1~2年内新近发生,且从未接受过任何抗高血压药物治疗的的1~2级高血压患者28例,并随机抽取同时期健康体检者28例进行对比观察。
1.2 方法 使用日本Colin公司生产的动脉硬化检测仪(VP 1000,PWV/ABI型)进行检查,心电图为窦性心率,检查前记录患者的年龄、性别、身高、体重,检查时间统一安排在上午9 10点,室温保持在25℃左右进行测定,以臂 踝脉搏波速度(Brachial ankle pulse wave velocity,baPWV)作为评估大动脉弹性指标。患者平卧于检查床安静静息 15 min以上,四肢缚4个示波血压袖带,连接好肢导联和心电图电极,并将1个心音图PCG 传感器放置在心电图胸导联V4的位置上,4个袖带同时充放气,并监测心电图和 PCG。取左右两侧的baPWV平均值进行统计分析。检查结束后的次日给予琥珀酸美托乐尔缓释片47.5 mg,每06:00~08:00口服,4周内每周门诊测量一次血压,降压达标后每4周测量一次血压,不达标者,根据心率变化,如果患者心率>60次/min,增加剂量至95 mg,每早一次口服;如果心率<60次/min,加用钠催离1.5 mg,每早一次口服。12周后重复检查baPWV前后进行对比分析。